Investors

Press Releases

Press Releases

May 05, 2022
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support further exploration of STAT3
Apr 08, 2022
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of ALL and AML KT-253 is a highly potent and selective heterobifunctional MDM2 degrader whose
Displaying 1 - 10 of 14